Clinical Experience With RIST-Based Multimodality Therapy in Relapsed Ewing Sarcoma: A Descriptive Single-center Case Series.
Mahdi Asleh, Yotam Eshel, Miriam Ben Harosh et al.
✦ AI-curated · Sources linked
Case in brief
This single-center case series described three patients with relapsed Ewing sarcoma treated with RIST (rapamycin, irinotecan, dasatinib, and temozolomide). The patient with measurable disease had an early partial response but progressed at 9 months. Two patients received RIST after local therapy while they had no evidence of disease; they maintained disease control for 41 and 44 months. Toxicities were manageable, primarily hematologic, and did not lead to treatment discontinuation.
What made this case unusual
RIST was used both for measurable relapsed disease and as post-local-therapy consolidation in patients with no evidence of disease, with prolonged disease control reported in the latter two cases.
Diagnostic / clinical pearl
Interpret outcomes in this small descriptive series by treatment context: the measurable-disease response was followed by progression, whereas prolonged disease control was reported with post-local-therapy consolidation.
Why it matters
The authors report that prolonged outpatient RIST administration was feasible; its role as multimodality consolidation requires prospective evaluation.